ICON
announced the launch of a new Cytometry Services offering from its Central Laboratories business unit. ICON Cytometry Services now offers clients two types of services to better support the testing requirements and development phase of a client’s compound.
ICON Cytometry Services’ full service solution allows clients to collaborate with ICON at the early stages of development to create compound-specific assays. Clients work with ICON Central Laboratories’ R&D team to develop a unique Flow Cytometry methodology, customised SOPs and agree on other special requirements including reporting. These customised Flow Cytometry panels can then be used throughout the compound development lifecycle. ICON Cytometry Services’ other service offering enables clients to choose from a wide range of fully validated assays and is often suited to the large scale, high-volume requirements of later phase global trials.
Commenting on the announcement, Tom O’Leary, President, ICON Central Laboratories, said, “Flow Cytometry has become a preferred testing method for many of our clients, particularly those with autoimmune, oncology and immunodeficiency compounds that require more specialised testing. Our new Cytometry Services offering provides clients with a better range of options, all of which are supported by a team of highly experienced scientists, robust instrumentation and rigorous quality control systems.”
ICON Central Laboratories offers global Flow Cytometry services from its laboratories in New York, Dublin, Bangalore and Singapore.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.